Alethia BioTherapeutics, Inc. Announces Collaborative Agreement With Biosite Incorporated for Antibody Development in Ovarian Cancer

MONTREAL, QUEBEC -- (MARKET WIRE) -- March 12, 2007 -- Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it has signed an exclusive collaborative agreement with Biosite Incorporated of San Diego for the development of recombinant monoclonal antibodies against validated targets in ovarian cancer. Under the terms of the collaboration, Alethia will provide Biosite with access to highly specific functional targets that will be evaluated as markers for ovarian cancer. In return, Biosite will provide Alethia with monoclonal antibodies for validated disease-specific targets to accelerate Alethia's therapeutic research development.

Back to news